Brainstorm Cell Therapeutics (BCLI) to Present Phase 2a NurOwn Data at American Academy of Neurology Meeting
Tweet Send to a Friend
Brainstorm Cell Therapeutics (NASDAQ: BCLI) today announced that results from its phase 2a study of NurOwn® in amyotrophic lateral sclerosis ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
